Basel gene therapy offers new hope for people with inherited blindness

A Basel-led trial has given some people with advanced retinitis pigmentosa the ability to detect light and recognise object outlines. The result, reported by Swissinfo on October 9, 2026, marks a significant step in the development of treatments for inherited blindness.

The study involved 10 participants, most of whom experienced some improvement after receiving optogenetic gene therapy. Researchers reported increased light sensitivity in seven people. In a separate assessment involving eight participants, four could see the outlines of small objects, including a matchbox.

That level of vision can have practical value. Recognising a door, a piece of furniture or a nearby object may help someone move through a familiar environment with greater confidence. The participants used special glasses that support the new visual signal and received training to interpret what they saw.

The work involved the Institute of Molecular and Clinical Ophthalmology Basel, affiliated with the University of Basel. Stefan Futterknecht, an IOB researcher and study co-author, described the findings as a milestone for restoring vision. The results appeared in the New England Journal of Medicine, giving the small trial international scientific visibility.

Optogenetics works by giving surviving retinal cells a new job. In advanced retinitis pigmentosa, the photoreceptor cells that normally detect light become severely damaged or stop functioning. The therapy uses a gene delivery method to make other retinal cells produce a light-sensitive protein.

Those cells then respond to light and send signals through the remaining retinal network. The approach does not repair every genetic defect that can cause retinitis pigmentosa. It aims to bypass part of the damaged visual system, which may allow it to serve people whose disease has different genetic origins.

The Basel researchers say this broad potential matters because retinitis pigmentosa covers a group of inherited retinal disorders rather than one single condition. The participants in the study had different underlying causes, yet the same optogenetic strategy produced signs of visual response.

The treatment currently depends on special glasses. The glasses detect visual information and project a modified light pattern into the eye, helping the newly light-sensitive cells distinguish shapes. Participants who practised more with the glasses generally saw better, according to the report. That finding places rehabilitation alongside molecular biology as a key part of the treatment.

The reported gains remain partial, and the study is too small to establish how widely the treatment will work. Ten participants cannot reveal the full range of benefits, risks or differences between patients with inherited retinal disease. The object-recognition assessment also involved eight people, so the finding that four participants saw small-object outlines needs careful interpretation.

The trial follows an initial study conducted in Paris five years earlier with a single participant. That man gained his first visual impressions after treatment, prompting researchers to test the method in a larger group. The new results provide additional evidence, while leaving important questions open about durability, consistency and everyday usefulness.

Futterknecht said patients remain far from reading or experiencing ordinary vision. The current system helps some people perceive basic shapes and light patterns. It does not return the detailed sight needed for books, faces at a distance or normal independent navigation in every setting.

Researchers are now working to improve several elements, including the proteins that make retinal cells light-sensitive. Future studies will need more participants, longer follow-up and clearer measures of daily function. They will also need to examine how much training each patient requires and whether the visual gains remain stable over time.